Category Archives: Uncategorized
Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
Below, we are re-publishing with permission the press-release issued by Miracor Medical on August 23, 2022 AWANS, Belgium–(BUSINESS WIRE)–Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to … Continue reading
BetaGlue announces the treatment of the first patient with BAT-90, taking radiotherapy inside solid tumours
Below, we are re-publishing with permission the press-release issued by BetaGlue Technologies on July 11, 2022 BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, is glad to announce that the first patient has been treated in a clinical … Continue reading
Clinical Accelerator announces collaboration with Verve Medical to conduct an early human feasibility study for treatment-resistant hypertension
Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Verve Medical, to conduct an early human feasibility study of their novel medical device for patients with treatment-resistant hypertension. World-wide, there … Continue reading
InterVene’s BlueLeaf Endovenous Valve Formation (EVF) System Granted Breakthrough Device Designation by the FDA
Below, we are re-publishing with permission the press-release issued by InterVene, Inc. on December 13, 2021 December 13, 2021 07:00 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVene Inc. announced today that it has received Breakthrough Device Designation by … Continue reading
Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in a first in-human trial of the coronary everolimus … Continue reading
Restore Medical Announces First in Human Trial for Treatment of Heart Failure in Patients
ContraBand™ technology helps restore the heart’s functionality and may significantly improve patients’ quality of life OR YEHUDA, Israel, Dec. 7, 2021 /PRNewswire/ — Restore Medical Ltd., a clinical-stage MedTech company developing cardiac implants for the treatment of congestive heart failure (CHF), today announced promising … Continue reading
Congress CSI Focus D-HF, Frankfurt, Germany, December 10-11th 2021
Clinical Accelerator is proud to have sponsored the CSI Focus D-HF (Device therapies in heart failure) conference this year in Frankfurt, Germany. Organized by Dr Horst Sievert, the two-day conference was one of the first to be in person in … Continue reading
Anteris Technologies CEO talks ‘outstanding results’ from first human DurAVR patients
Anteris Technologies CEO talks ‘outstanding results’ from first human DurAVR patients
Clinical Accelerator collaborates with CroíValve on a study for Tricuspid Regurgitation
Clinical Accelerator has recently entered into a new collaboration with CroíValve – a medical device company from Ireland – who is developing a novel, easy to use percutaneous solution for treating patients with severe Tricuspid Regurgitation (TR). Tricuspid Regurgitation … Continue reading
VisCardia Announces Its Novel Heart Failure Therapy Receives Breakthrough Device Designation From the FDA
Below, we are re-publishing with permission the press-release issued by VisCardia Inc. on April 23, 2020 PORTLAND, Ore., April 23, 2020 (Newswire.com) – VisCardia Inc., a privately held medical device developer, announced today it has been granted Breakthrough Device Designation … Continue reading
You must be logged in to post a comment.